Influence of Natural Lung Surfactant Inhalations on Clinical Symptoms and Pulmonary Function Parameters in Patients with Bronchial Asthma. Communication 2

Abstract

Background: Damage to lung surfactant (LS) enabling the lung local immunity may contribute to the development of bronchial inflammation in patients with bronchial asthma (BA). Methods and Results: A 70-day course of 21 LS (Surfactant-BL) inhalations at the dose of 25 mg was added to inhaled corticosteroids (ICS) and short/long-acting bronchodilators or combined inhalers in 13 BA patients. After 21 inhalations, many patients reported lower frequency of cough and profuse expectoration, fewer night and day attacks, resolution of wheezing, resolution or lower frequency of bronchospasm episodes under moderate exercise, and termination (1 patient) or double reduction (8 patients out of 13) of the ICS dose. The values of PFPs in patients at Days 250 and 340 did not differ significantly from the values achieved at Day 41. The mean values at Days 250 and 340 were as follows: FVC =86.4±6.43 (%), FEV1=61.4±8.41 (%), FEV1/FVC =66.5±8.87 (%). Conclusion: LS inhalations improve the condition of patients with BA, allow ICS dose reduction by 2 times, and improve pulmonary function parameters. A total of 70% of patients had quite a long remission of BA symptoms following a 21-inhalation therapy course of the formulation.

Keywords

• lung surfactant
• bronchial asthma
• inhaled corticosteroids
• pulmonary function
• dose